The object is to provide a peptide having higher affinity to hemagglutinin, a peptide having a high inhibitory activity on the infection with an influenza virus, and a pharmaceutical composition comprising any one of the peptides. Peptides having a mutation in the sequence: ARLSPTMVHPNGAQP (peptide A-1; SEQ ID NO:1) are prepared, and screening is made for a peptide having higher affinity to hemagglutinin. As a result, polypeptides comprising the sequences depicted in SEQ ID NOs:2-7, 9-10 and 12-18 can be obtained. These peptides can be used as the peptide mentioned above. In a peptide having the sequence depicted in SEQ ID NO:3, when the C-terminus of the sequence of SEQ ID NO:3 is removed so as to allowing ARLPR or ARLP to remain, the inhibitory activity of the peptide on the infection with an influenza virus can be increased. An inhibitor of the infection with an influenza virus or a prophylactic/therapeutic agent for influenza can be prepared by formulating the above-mentioned influenza virus receptor-binding peptide.
展开▼
机译:目的是提供对血凝素具有更高亲和力的肽,对流感病毒感染具有高抑制活性的肽以及包含任何一种肽的药物组合物。制备具有序列突变的肽:ARLSPTMVHPNGAQP(肽A-1; SEQ ID NO:1),并筛选对血凝素具有更高亲和力的肽。结果,可以获得包含SEQ ID NO:2-7、9-10和12-18中描述的序列的多肽。这些肽可以用作上述肽。在具有SEQ ID NO:3所示的序列的肽中,当去除SEQ ID NO:3的序列的C-末端以允许保留ARLPR或ARLP时,该肽对感染的抑制活性。流感病毒可以增加。流感病毒感染的抑制剂或流感的预防/治疗剂可以通过配制上述流感病毒受体结合肽来制备。
展开▼